>PROKKA_00001 hypothetical protein
MRFASTFSIVTDYKIRENTIKSWVSKISNYIYNDDELTKRTSKWIKELYPDINEMQIALR
FNEILKQAFENSIKIVLIIDELTNEQKDTIKNIIGAFKLNNNSKNNSIEFASYVVRLEQK
VNIVDDNAQYALSYQE*
>PROKKA_00002 putative hydrolase
VNKELIIEKTKEYVKSRLEGEGSGHDWYHILRVYNNAIDIARNEENVDIFIVKLGALLHD
IADHKFGYNDDDRKNIISGFLSKYDVSQEDIKEVVYITNYISFKGGTNNHVMKSIEGKIV
QDADRLDAMGAIGISRAFTYGGYINRPMYDVNPNNIEHEKRDGYINTDTITHFYEKLLLL
KDRMNTNTGRKKAIIRHKTMEMFLDMFFKEWNGEI*
>PROKKA_00003 transcriptional regulator BotR, P-21
MNDLFYAIENLKHDNQHFDFIEMSLKKYIEKTSKKYNLYYDYYNDILYHLWKELIEINLK
NFNSELDLRKYISTSIKRYCINICKKKNRDKKIIYNLEATYKKLDAVNVYSLYCEDFEFL
DLISILNYKEKQIIYMKFFECRKDNEIARRLHLSRQSIYKIRIKSLKKLYPIVMQLVNI*
>PROKKA_00004 Hemagglutinin components HA-22/23/53 precursor
MSLSIKELYYTKDKSINNVNLADGNYVVNRGDGWILSRQNQNLGGNISNNGCTAIVGDLR
IRETATPYYYPTASFNEEYIRNNVQNVFANFTEASEIPIGFEFSKTAPSNKGLYMYLQYT
YIRYEIIKVLRNTVIERAVLYVPSLGYAKSIEFNSGEQIDKNFYFTSEDKCILNEKFIYK
KIDDATLAKESNNLNNNINFNTSQTILPYPNGLYVINKGDGYMRTNDKDLIGTLLIESNT
SGSIIQPRLRNTTRPIFNTSNPTLFSQEYTEARLNDAFNIQLFNTSTALFKFVEEAPDNK
NISMKAYNTYEKYELINYQNGNIGDKAEYYLPSLGKCEVSDAPSPQAPVVETPVEQDGFI
QTGPNENIIVGVINPSENIEEISTPIPDDYTYNIPTSIQNNGCYVLFKVNTTGVYKITTK
NNLPPLIIYEAIGSSNRNMNLNNLSNDNIKAIKYITGLNRSDAKSYLVVSLFKDKNYYIR
IPQIPSSTTNQINFKRDLGNLQILADSTVNIIDNLNSSGLHYYTRQSPDVGDYISYEFII
PGNFNNKDKSNLILYTTNNQSNGDLYRVTESINGYNLINIKSYSSLLNNNESIQLLNGAI
YILKVKIAQLNNYNIRFNINITN*
>PROKKA_00005 HA 17 kDa subunit
MSSERTFLPNGNYKIKSLFSDSLYLTYLSGSLSFLNTSSLDNQKWKLEYISSSNGFRFSN
VAEPNKYLAYNDYGFIYLSSSSNNSLWNPIKIAINSYIICTLSIVNVTDYAWTIYDNNNN
ITDQPILNLPNFDINNSNQILKLEKL*
>PROKKA_00006 hypothetical protein
MSQTNANDLRNNEVFFISPSNSTNKVLDKISQSEVKLWSKNLGSNQKWRLIYDTNKQAYK
IKVMDNTSLILTWDAPLSSVSVKTDTNTNNQYWYLLQDYISRNVIIRNYMNPNLVLQYNT
DDTLIVSTQTSSNNQFFKFSNCIYEALNNRNCKLQTQLNSDRFLSKNLNSQIIVLWQWFD
SSRQKWLIEYNETKSAYTLKCQENNRYLTWIQNSNNYVETYQSTDSLIQYWNINYLDNDA
SKYILYNLQDTNRVLDVYNSQIANGTHVIVDSYHGNTNQQWIIILI*
>PROKKA_00007 Botulinum neurotoxin type E precursor
MDINDDLNINSPVDNKNVVIVRARKTNTFFKAFKVAPNIWVAPERYYGEPLDIAEEYKLD
GGIYDSNFLSQDSERENFLQAIITLLKRINNTISGKQLLSLISTAIPFPYGYVGGGYSSP
NIFTFGKTPKSNKKLNSLVTSTIPFPFGGYRETNYIESQNNKNFYASNIVIFGPGSNIVE
NNVICYKKNDAENGMGTMAEILFQPLLTYKYNKFYIDPAMELTKCLIKSLYFLYGIKPSD
GLVVPYRLRTELDNKQFSQLNIIDLLISGGVDLEFINTNPYWFTNSYFSNSIKMFEKYKN
IYETEIEGNNAIGNDIKLRLRQKFENSVQDIWNLNLNYFSKEFNSIIPDRFSNALKHFYR
KQYYTMDYTDNYNINGFVNGQINTKLPLSDKNTNIISKPEKVVNLVNENNISLMKSNIYG
DGLKGTTEDFYSTYKIPYNEEYEYRFNDSDNFPLNNISIEEVDSIPEIIDINPYKDNSDN
LVFTQITSMTEEVTTHTALPINYLQAQITTNENFTLSSDFSKVVSSKDKSLVYSFLDNLM
SYLETIKNDGPIDTDKKYYLWLKEVFKNYSFDINLTQEIDSSCGINEVVIWFGKALNILN
TSNSFVEEYQNSGPISLISKKDNLSEPNIEIDDIPDSLLGLSFKDLNNKLYEIYSKNIVY
FKKIYFNFLDQWWTEYYSQYFELICMAKQSILAQESLVKQIIQNKFTDLSKASIPPDTLK
LIKETTEKTFIDLSNESQISMNRVDNFLNKASICVFVEDIYPKFISYMEKYINNINIKTR
EFIQRCTNINDNEKSILINSYTFKTIDFKFLNIQAIKNFFNSQVEQVMKEMLSPYQLLLF
ATRGPNSNIIEDISGKNTLIQYTESVELVYGVNGESLYLKSPNETVEFSNNFFTNGLTNN
FTICFWLRFTGKDDDKTRLIGNKVNNCGWEIYFEDNGLVFEIIDSNGNQESVYLSNVINN
NWYYISISVDRLKDQLLIFINDKNVANVSIEQILNIYSTNVISLVNKNNSIYVEELSVLD
KTVTSEEVIRNYFSYLDNSYIRDSSKSLLEYNKNYQLYNYVFPKTSLYEVNDNNKSYLSL
KNTDGINIPSVKFKLINIDESKGYVQKWDECIICVSDGTEKYLDISPENNRIQLVSSKDN
AKKITVNTDLFRPDCITFSYNDKYFSLSLRDGDYNWMICNDNNKVPKGAHLWILES*
>PROKKA_00008 Botulinum neurotoxin type C1 precursor
VDIRKLGDVSIMPITINNFNYSDPVDNKNILYLDTHLNTLANEPEKAFRIIGNIWVIPDR
FSRDSNPNLNKPPRVTSPKSGYYDPNYLSTDSEKDTFLKEIIKLFKRINSREIGEELIYR
LATDIPFPGNNNTPINTFDFDVDFNSVDVKTRQGNNWVKTGSINPSVIITGPRENIIDPE
TSTFKLTNNTFAAQEGFGALSIISISPRFMLTYSNATNNVGEGRFSKSEFCMDPILILMH
ELNHAMHNLYGIAIPNDQRISSVTSNIFYSQYNVKLEYAEIYAFGGPTIDLIPKSARKYF
EEKALDYYRSIAKRLNSITTANPSSFNKYIGEYKQKLIRKYRFVVESSGEVAVDRNKFAE
LYKELTQIFTEFNYAKIYNVQNRKIYLSNVYTPVTANILDDNVYDIQNGFNIPKSNLNVL
FMGQNLSRNPALRKVNPENMLYLFTKFCHKAIDGRSLYNKTLDCRELLVKNTDLPFIGDI
SDIKTDIFLSKDINEETEVIDYPDNVSVDQVILSKNTSEHGQLDLLYPIIEGESQVLPGE
NQVFYDNRTQNVDYLNSYYYLESQKLSDNVEDFTFTTSIEEALDNSGKVYTYFPKLADKV
NTGVQGGLFLMWANDVVEDFTTNILRKDTLDKISDVSAIIPYIGPALNISNSVRRGNFTE
AFAVTGVTILLEAFPEFTIPALGAFVIYSKVQERNEIIKTIDNCLEQRIKRWKDSYEWMI
GTWLSRITTQFNNISYQMYDSLNYQADAIKDKIDLEYKKYSGSDKENIKSQVENLKNSLD
VKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLKTKTELMNLIDSHNIILVGEV
DRLKAKVNGSFENTIPFNIFSYTNNSLLKDIINEYFNSINDSKILSLQNKKNALVDTSGY
NAEVRVEGDVQVNTIYTNDFKLSSSGDKIIVNLNNNILYSAIYENSSVSFWIKISKDLTN
SHNEYTIINSIKQNSGWKLCIRNGNIEWILQDINRKYKSLIFDYSESLSHTGYTNKWFFV
TITNNIMGYMKLYINGELKQSERIEDLDEVKLDKTIVFGIDENIDENQMLWIRDFNIFSK
ELSNEDINIVYEGQILRNVIKDYWGNPLKFDTEYYIINDNYIDRYIAPKSNILVLVQYPD
RSKLYTGNPITIKSVSDKNPYSRILNRDNIMFHMLYNSGKYMIIRDTDTIYARQGGECSQ
NCVYPLKLQSNLGNYDIGIFSIKNIVSQNKYCSQIFSSFRENTMLLADMYKPWRFSFKNA
YTPVAVTNYETKLLSTSSFWKFISRDPGWVE*
>PROKKA_00009 hypothetical protein
VVEEQQLNKDLKKVKEKFIKALVRTLNEENENRVYDGKKPLGVCFMVSIIDKQLHKYKDF
LRDLSNGYTFNGYEEDESGYSNGKISLFIEKHIEDKESNLWASTYKQDYWYSIEFKYDTR
DWGYCQCEPNDKGYNEEHDCCGKTCDWDAPSFAITKEYDLGTCSWDGFQRDYWEYEKMFK
SKEENKNKRVEDEIKERRKQEIMEQINLLNQELISLES*
>PROKKA_00010 PQ loop repeat
MSTQIISFLLQLSGSILLLGGYFPQIIQLYKTKKSEDISLSFWVILTTGLFCIAFNMLIS
HVPNFIMVTQFLNAIIALWVLVLVKKYK*
>PROKKA_00011 Nucleoside 2-deoxyribosyltransferase
MKNINIESTTTEQKQGYIAGGLFNEADISQRLKEGRLLRENTNIDFYNPIEAPCNDKSKL
PTDQDIFNMDAQKVLQSHTVIADISTRDEGVMAELGIAWTCNFIHHLAEQGYTLEDILKY
IPKKQTYANLPDIRKGTAHNYKGNYIPVGFNQFIVGMIRQMGNVYDGFNDILKDLKKDNK
*
>PROKKA_00012 Thymidine kinase
MAQLYYRYGVLNSAKSANLIMAVHNYDKKNRRVVVLKPKIDTRSKPNIVESRVGISHACI
DFDKNENLFELVNTLNSKDTIHAVFVEEVQFITKEQAKQLHNIVHELNIPTLGYGLKNTY
IDGELFEGSKAMLFYADKIEEIKDVCEYCNKKATQNLRVVNGEPIYRGETIRIGDVNSNV
EEYYVPVCGYHYYHPELK*
>PROKKA_00013 hypothetical protein
MILEFNGYKIVTDDKQFIVQKKKVVQAGRLTKEENIGKEYWEDVGYFTNLNFALKFIKKT
VLLDNDDLKVIMDRLNQLEGKIDEFTKKLEE*
>PROKKA_00014 putative NHN endonuclease
MKINNFNVDLYKGKGYQCNIGDTVNIDIKDVSAHSKNKIKIQCDKCKTNIKEITIASLHH
SKSYQEGNYICYECKEKILPQMKCEVCGSTHKVTNYLNEGNLLCQRHQRILRKKGDIKRT
IYDPNEIHIYEDYAEFDTYDINGDINGIFKIDLDVVNFVKSHKIYKHKDGYACYKFKDKN
NKTKNMRLHRYIMNVHNAKDKSIIVDHINRDKQDNRRHNLRLATFKDNVVNTGMFSTNTS
GHKGISWNKQRKTWEVYIHQYNKKIGLGYYKDYDKAVKVREIAEIIYFGSNNPEYNKLIK
KYIDNPKIQHILLNHREEYIND*
>PROKKA_00015 DNA topoisomerase 4 subunit B
MTKQKVINYYDDRGKVRNKIGIWLGSNTHQAVIHTIKELTANSGDILIENIGSKIIWTIY
DDKTVEIYDDGTGLPLEGTTIIKKKDVKGRETTEVKSNYELLLLTLFAGTKHNGLETGEK
NTGSNGVFNTVLTYSSEYVEYEIGRPDGNIYFCSFKEGFIDKELQIIGETDKTYTRIKYK
LSDQVYTENKFTFDEICDICQKQSALIKKPIIIVDETTNQEVIYNLSNGLEELFNVYLHD
KSKSCKDIIIKDSFSQDVTFENHQYKDNMNYELILNYTIEENNNVNMDFLNRSELIHHGT
IQDGIIDGLRKCIHNFINKEGLYNKKESNISKDDILCGLNYMIDFSSLHPNMYSNQTKFE
TKVKYFKTHLTKSIMDYFEIYAIEHKDEMLKIANKLLINKRSREKAEVNRKEIRKKLEQD
VNKSTGRPDKFVPCQSKNKHEKELILIEGDSSLNSVKLSRNKKVHSIYPLKGKPLNTLKK
SLDDILKNEEVTDIFQILQCGMQYKGKSIKGVKQFNIDDLDVDKIIIFSDEDEDGLHIRS
LVIGIFYVLAPKIIAQGHLYVLDSPLYRIDTKNKTYLAYNEKEKNNIIKNLNNQNEKFTD
SRFKGLGGLSVDLLSETAMNIENRKLTQITINDIEKAKQVLEMFMDDDSTDRKQYIEKFG
EQYFDYSIYEI*
>PROKKA_00016 DNA gyrase subunit A
MIIQSEVSEAIREYYMPYAMKVITDRALPDVRDGLKPIARRILWTMWNNGLLHNKPRAKC
GKVVGDILKIHNHGDSSVYNALSLLTDQNESLLQGFIDGEGAFGKIYSKDSPSAMRYTSA
RLNKFSQEMFKNIDKDIVKFIGEDKEHLQPLCLPNTFPNILIKPNSGVAVGEACNWCSFN
LVEVCNLTQEYIKNNNINVIDYLTAPDFSTGGYIITSNFDLNKIYETGRGSFRLQAKYKY
NEKENTIEVYEIPYNTTVEDIKKEITNLMKSDRLKEVKDVKDGTGYNTKLKKEEMGVIIE
IKNNVNPNRLMKKLFKYTSLNKSFNCNFNCLVNYRPQVLGIKQILNEWLKFRIECVKESI
KYDLNNKIKLLHFLKGLEKVLLNIDKAVEIIRYSKTDSLIINNLRKEFNIDEQQANDIAN
MKLKNINEQYINNKVQSILEIQKEHDKLKGLLQSEKDIQNIIIDELEKVKNNYGKARKTE
LLNKHEIEDTSHEDLVEDFNPTIVLTEQQYIKKNRVFSQSQKLKDDDKILQFHQCNNKDD
LLLFTNKGNVLIRKVYELDEHKPSTYGDFLPNLLGEHLENDEKVIYISTTKDYKGSVISV
FENGYIARTDLQTYKPKQNRQIPMSAYNTDIGIVSIQLITNDTDILLVSQEGKALIINTS
QIRPTKSRNTQGVSGMKIDTETNKIIASIIGVTVDDNFNIETEKGKSKFIMLNDIAPNNK
ESMTDYLKGNRNTQGNFIYNTRQKNDRVIKLTKQEN*
>PROKKA_00017 5' nucleotidase, deoxy (Pyrimidine), cytosolic type C protein (NT5C)
MENINIHNKNLEIICDMDDVLVNLSEFVVNQYNKDFDDNMNWQDNKSYWWGDCKKAPKSY
FEQLLLKKETFINPKPTENSIKTLNKLHEEGFKIIFCTYPQYNSDYCIKEKIQWLQQYFK
WFNIDENLVFTHNKGLLAKSNRILLDDNLDHIFSFINNGGIGCIFNQNWNGNVGNRRFIG
YRITRFEEFYTVVHNLENELVAKKNYETNVLKEISFHNKYYVK*
>PROKKA_00018 hypothetical protein
LQEYEGYYFKKHPRARNKPFKSPIHPSINVWAINRMTMRNMKSKWKEFGLWLVNKLGYEN
LHIEKFQITMKNYYGNRRRRDNDNQSPKFLLDPLVESGMLVDDDYKHLNPLIIMGGYDKE
NPRMEIIVDILE*
